Compare Moody's Corporation (MCO) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Medpace Holdings Inc — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Moody's Corporation is far larger — about 4.7× Medpace Holdings Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Medpace Holdings Inc for 14 Days on average.
| MCO | MEDP | |
|---|---|---|
Market Cap | $79.44B | $16.82B |
Volume | 526,684 | 223,093 |
Sector | Financials | Health |
52-Week High | $539.61 | $630.19 |
52-Week Low | $412.23 | $393.42 |
Typical Hold Time | 132 Days | 14 Days |
Enterprise Value | $85.46B | $16.44B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals. Revenue grew to $7.72B in 2025, with net income margin expanding to 34.25%. Recent news highlights Moody's top RiskTech100 ranking and expansion into Asia-Pacific via a PhilRatings stake. The stock faces resistance near $461, with support at $454.
Outlook remains positive given consistent earnings beats, high profitability, and a $536.40 analyst price target implying 17% upside. Risks include high valuation multiples and macroeconomic sensitivity. Institutional sentiment is bullish with 56% buy ratings, though technical indicators suggest near-term caution.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
